Business Description
Enliven Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US29337E1029
Description
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 755.67 | |||||
| Equity-to-Asset | 0.91 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -118 | |||||
| 3-Year EPS without NRI Growth Rate | -63.4 | |||||
| 3-Year FCF Growth Rate | -99.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 39.84 | |||||
| 9-Day RSI | 43.66 | |||||
| 14-Day RSI | 46.97 | |||||
| 6-1 Month Momentum % | 47.12 | |||||
| 12-1 Month Momentum % | -9.69 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 10.28 | |||||
| Quick Ratio | 10.28 | |||||
| Cash Ratio | 9.78 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -0.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -35.75 | |||||
| ROA % | -29.32 | |||||
| ROIC % | -810.71 | |||||
| ROC (Joel Greenblatt) % | -6397.75 | |||||
| ROCE % | -36.23 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 2.88 | |||||
| Price-to-Tangible-Book | 2.88 | |||||
| EV-to-EBIT | -6.38 | |||||
| EV-to-EBITDA | -6.4 | |||||
| EV-to-FCF | -8.67 | |||||
| Price-to-Net-Current-Asset-Value | 2.95 | |||||
| Price-to-Net-Cash | 3.12 | |||||
| Earnings Yield (Greenblatt) % | -15.67 | |||||
| FCF Yield % | -7.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ELVN
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Enliven Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.738 | ||
| Beta | 0 | ||
| Volatility % | 44.34 | ||
| 14-Day RSI | 46.97 | ||
| 14-Day ATR ($) | 1.811606 | ||
| 20-Day SMA ($) | 18.691 | ||
| 12-1 Month Momentum % | -9.69 | ||
| 52-Week Range ($) | 9.8 - 26 | ||
| Shares Outstanding (Mil) | 46.81 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Enliven Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Enliven Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Enliven Therapeutics Inc Frequently Asked Questions
What is Enliven Therapeutics Inc(ELVN)'s stock price today?
The current price of ELVN is $17.18. The 52 week high of ELVN is $26.00 and 52 week low is $9.80.
When is next earnings date of Enliven Therapeutics Inc(ELVN)?
The next earnings date of Enliven Therapeutics Inc(ELVN) is 2024-05-10 Est..
Does Enliven Therapeutics Inc(ELVN) pay dividends? If so, how much?
Enliven Therapeutics Inc(ELVN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers